Blood-based biomarkers have the potential to revolutionize clinical practice and clinical trials in Alzheimer disease (AD). However, to date, this “holy grail” opportunity has not been realized owing to a broad range of issues, including the lack of a clearly defined context of use (COU), lack of standardization of methods, and numerous failures at replication. Recently, however, a shift in the paradigm has occurred, with my colleagues and I proposing specific COUs for blood-based biomarkers along with potential paradigms for advancing from discovery to clinic and potential acceptable standards.1,2
Connecting Longevity with Vitality and Resilience (CLeVR)
The McMaster Institute for Research on Aging (MIRA) welcomed PNA's very own Dr. Rosano to campus on May 13, 2026, for the second annual Suzanne Labarge Lecture in Aging, drawing a large and engaged audience to hear about research in brain health and resilience in...
